Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497678 | 0.68 | — | — | |
| SCHEMBL25354296 | 0.66 | CYP1A2 (0.43) | KMT2A | |
| SCHEMBL25354300 | 0.66 | CYP1A2 (0.43) | KMT2A | |
| SCHEMBL31708528 | 0.64 | CNR2 (0.32) | — | |
| SCHEMBL1038218 | 0.60 | ALDH1A1 (0.31) | — | |
| SCHEMBL970408 | 0.60 | NPC1 (0.49) | MAP4K1KMT2A | |
| SCHEMBL20570053 | 0.58 | TRPM8 (0.34) | KMT2A | |
| SCHEMBL21632736 | 0.56 | L3MBTL1 (0.42) | — | |
| SCHEMBL21095492 | 0.56 | MAP4K1 (0.36) | MAP4K1KMT2A | |
| SCHEMBL3013035 | 0.56 | MALT1 (0.33) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240052428-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING LYMPHOMA AND RELATED CONDITIONS | THE BROAD INSTITUTE, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4308733-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING LYMPHOMA AND RELATED CONDITIONS | The Broad Institute, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197933-A9 | COMPOSITIONS AND METHODS FOR CHARACTERIZING LYMPHOMA AND RELATED CONDITIONS | THE BROAD INSTITUTE, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022197933-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING LYMPHOMA AND RELATED CONDITIONS | THE BROAD INSTITUTE, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-9091697-B2 | Use of 2 anti-SPARC antibodies to predict response to chemotherapy for pancreatic adenocarcinoma | ABRAXIS BIOSCIENCE, LLC (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130172261-A1 | USE OF 2 ANTI-SPARC ANTIBODIES TO PREDICT RESPONSE TO CHEMOTHERAPY | ABRAXIS BIOSCIENCE, LLC (US) | 2013-07-04 | — | — | US | disclosed |